FDA 483 - AstraZeneca Pharmaceuticals LP - January 19, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
AstraZeneca Pharmaceuticals LP in Frederick, MD, a drug substance manufacturer, received a Form 483 with two observations. The inspection revealed issues with computer system controls, specifically alterable date/time stamps on systems used for drug substance testing, and inadequate use of sporicidal agents in ISO 5 classified processing areas due to unsupported contact times. These findings indicate significant concerns regarding data integrity and environmental control.
ID · 05295a30-e31b-4220-a8bf-8906643f78cd